Introduction
The growth of new blood vessels from the existing vasculature, a process known as angiogenesis, is crucial during embryonic and postnatal organ development as well as in various remodelling processes of the adult organism. 1 VEGFs are central regulators of pre-and postnatal angiogenesis; their intracellular effects are mediated by three tyrosine kinase receptors, VEGFR1 (FLT-1), VEGFR2 (KDR/FLK-1), and VEGFR3 (FLT-4). 2, 3 All three receptors are highly expressed in endothelial cells (ECs) during development, and inactivation of any receptor leads to vascular abnormalities and embryonic lethality between embryonic day 8.5 and 10.5 in mice. 3 VEGFR2, mainly activated by VEGF-A, plays a key role in the transduction of angiogenic signals and controls EC morphology, chemotaxis, and proliferation. 1 -3 Ligand binding induces VEGFR2 dimerization and activation of the receptor kinase activity, resulting in receptor autophosphorylation. Phosphorylated receptors, in turn, recruit interacting proteins and induce the activation of various intracellular signalling pathways. 3, 4 Phosphorylation at Y1175, for example, was shown to result in phospholipase (PLC) g-dependent calcium mobilization and protein kinase C (PKC) activation, which in turn leads to activation of the mitogen-activated protein kinase pathway and consecutively increased proliferation. In addition, Y1175 phosphorylation induces phosphatidylinositol-4,5bisphosphate 3-kinase (PI3K)-dependent Akt activation, thereby enhancing cell survival. Phosphorylation at residue Y951 facilitates Src activation, which in turn controls cytoskeletal organization and cell migration. 3, 4 Other signalling events induced by VEGFR2 activation are activation of focal adhesion kinase (FAK), paxillin, or small GTPase Cdc42. 3 Whether the process of VEGFR2 autophosphorylation can be modulated by factors other than VEGF-A binding is not well understood. In vitro studies suggested that heterotrimeric G-proteins of the G q/11 family may contribute to VEGF-induced effects such migration and proliferation, 5, 6 and it was suggested that members of this G-protein family are required for VEGF-induced VEGFR2 autophosphorylation. 6 The G q/11 family consists of two ubiquitously expressed members, G q and G 11 ; their a-subunits show a sequence homology of 90% on the amino acid level. 7 A large number of G-protein-coupled receptors (GPCRs) mediate their intracellular effects through G q/11 , for example the receptors for permeability-enhancing factors histamine or thrombin. 8, 9 The major downstream effector pathway of Ga q/11 is PLCb-dependent production of 1,4,5-trisphosphate (IP 3 ) and diacyl glycerol (DAG), giving rise to IP 3 -dependent intracellular calcium mobilization and induction of various DAG-dependent effects such as PKC activation. 9, 10 Ga q/11 -dependent calcium mobilization has been shown to facilitate secretion and cellular contractility; it also plays a role in activation of extracellular signal-regulated kinases 1/2 (ERK1/2) and the FAK family member Pyk2. 9, 10 Ga q/11 -dependent PKC activation furthermore facilitates activation of ERK1/2 and consecutive changes in transcriptional activity. 9, 10 In addition to the canonical PLCbdependent signalling cascade, activation of alternative effectors, such as Rho-specific guanine nucleotide exchange factors, PKC z, or PI3K, has been described. 10 In ECs, Ga q/11 is crucial for GPCR agonist-induced phosphorylation of myosin light chain (MLC) kinase, a major determinant of cellular contractility and fluid extravasation. 8, 11 In addition, mice with tamoxifen-inducible, EC-specific deficiency for Ga q/11 are protected from anaphylactic shock induced by agonists at G q/11 -coupled receptors such as histamine or platelet-activating factor. 8 However, whether Ga q/11 also plays a role in VEGF-induced changes in permeability or VEGF-induced angiogenesis in vivo is unknown. We show in this study that endothelial Ga q/11 is crucial for VEGF-induced signalling events and critically contributes to VEGFdependent permeability control and angiogenic behaviour in vitro and in vivo.
Methods

Experimental animals
The generation and genotyping of mice with tamoxifen-inducible, ECspecific deficiency for Ga q/11 has been described previously. 8 Littermate iEC-Ga q/11 -KOs (Tie2CreERT2 + ; Gnaq fl/fl ;Gna11 2/ 2 ), iEC-Ga q -KOs (Tie2CreERT2 + ;Gnaq fl/fl ;Gna11 +/+ ), Ga 11 -KOs (Gnaq fl/fl ;Gna11 2/2 ), and control mice (Gnaq fl/fl ;Gna11 +/ + ) were generated by intercrossing Tie2CreERT2 +/2 ;Gnaq fl/fl ;Gna11 +/2 mice. Littermate iEC-Ga q -KOs and control mice were generated by intercrossing Tie2CreERT2 +/2 ;Gnaq fl/fl mice. For induction of Cre-mediated recombination in adult mice, 8-to 12-week-old mice were injected intraperitoneally (i.p.) with 1 mg of tamoxifen dissolved in 50 mL of Miglyol oil on five consecutive days (all genotypes); experiments were performed 1 and 2 weeks after the end of induction.
To induce Cre-mediated recombination in newborn mice, pups received intraperitoneal injections of 50 mg of tamoxifen in 50 mL of Miglyol on postnatal days (P) 1, 2, and 3, followed by analysis on Day 6.
To visualize retinal endothelia barrier opening, high mol. wt 2000 kDa FITC dextran (25 mg/mL) was injected intracardially into p6 pups anaesthetised by isoflurane inhalation. After 3 min, pups were sacrificed, the eyes were enucleated, fixed, and retinal tissue was processed for VE-cadherin staining and confocal IF microscopy.
For in vivo permeability assays in adult mice (Miles assay), the histamine H1 receptor antagonist pyrilamine maleate salt (4 mg/kg body weight in 0.9% saline) was injected i.p. 30 min before Evans blue injection to block the effects of local histamine release due to injection-induced mast cell activation. One hundred microlitres of Evans blue (0.5% in sterile saline) were injected in isoflurane anaesthesia into the tail vein and allowed to circulate for 10 min. The dorsal flank was bilaterally shaved, and 20 ml of proteaseactivated receptor-1 (PAR-1) peptide (an activator of the thrombin receptor subtype protease-activated receptor-1, 10 mg), VEGF (100 ng), and PBS or saline were injected intradermally. Twenty minutes later, mice were sacrificed by cervical dislocation and opening of the thorax, and the dorsal skin was excised. Evans blue was extracted by immersion in formamide for 48 h at 608C and the amount of blue dye was quantified by spectrometry at 620 nm.
To analyse EC barrier opening in the adult mouse ear, mice were anaesthetized by isoflurane, and 10 mL of PBS, VEGF (100 ng/mL), or PAR-1 peptide (1 mg/mL) were injected into the ear. After 10 min, mice were sacrificed and the ears removed and fixed with 4% PFA for 30 min. The ventral part of the ear skin was removed together with cartilage and muscles, and the dorsal dermis was subjected to immunohistochemical staining.
All animal experiments were performed as approved by local authorities (Regierungspräsidium Darmstadt, Hessen, Germany) and according to the Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
Antibodies and dyes
Antibodies to Ga q/11 (sc-392), p-ERK1/2 (sc-7383), and c-Src (sc-18) were from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies to p-Src (2113), GAPDH (2118), VEGFR2 (2479), p-VEGFR2 (Tyr1175; 3770), p-VEGFR2 (Tyr951; 4991), cleaved caspase-3 (9661), ERK1/2 (137F5), p-Akt (Ser473; 4060), p-PLCb 3 (Ser537), or p-MLC2 (Ser19) were from Cell Signaling (Danvers, MA, USA). Antibodies directed against Brdu (347580), PECAM1 (550274), b-catenin (610153), and Ga q (612705) were from BD Biosciences (San Jose, CA, USA). Antibodies to Desmin (ab8592) and Ki67 (ab15580) were from Abcam (Cambridge, UK). Anti-Zo-1 (617300), Alexa Fluor-488-or -594-labelled secondary antibodies, isolectin B4-Alexa Fluor-488/-594 (I21411/I21413), Hoechst 33342 (H1399), Fluo-4 AM (F14202), and Brdu were from Life Technologies (Carlsbad, CA, USA). Biotinylated IB4 (L2140) was from Sigma-Aldrich (St Louis, MO, USA), and anti-VEGFR3 (AF743) was from R&D Systems (Minneapolis, MN, USA). The anti-VEGF antibody B20-4.1.1 was a kind gift from Genentech (San Francisco, CA, USA). The following antibodies for Cdh5/VE-cadherin were used: VE-cadherin (c-19; sc-6458) from Santa Cruz for western blotting of murine samples, VE-cadherin (2500) from Cell Signaling for western blotting and IF staining in human umbilical vein endothelial cells (HUVECs), and VE-cadherin (555289 and 555661) from BD Biosciences for IF staining in murine tissues. Anti-p(Tyr731)-VE-cadherin (441145G) and anti-p(Tyr658)-VE-cadherin (441144G) were from Life Technologies; anti-p(Tyr 685)-VE-cadherin (CP-1981) was from ECM Biosciences (Versailles, KY, USA).
Agonist and inhibitors
TNF-a (410-MT), VEGF-A/VEGF-165 (293-VE), and fibroblast growth factor 2 (FGF-2; 233-FB) were from R&D Systems. Thrombin (T4648), histamine (H7125), PAR-1 peptide (SFLLRN-NH 2, s1820), FITC dextran (70 kDa: FD70 and 2000 kDa: FD2000S), tamoxifen (T5648), and pyrilamine maleate salt (P55144) were from Sigma-Aldrich. PP2 (172889-27-9) was from Merck Millipore; protease inhibitors were from AppliChem (Darmstadt, Germany). The anti-VEGF antibody B20-4.1.1 was a kind gift from Genentech (San Francisco, CA, USA).
HUVEC culture and siRNA transfection
HUVECs (CC-2517) were cultured in EGM2 complete medium [EGM2 medium (CC3156) and growth factor supplements (CC-4176); Lonza, Basel, Switzerland]. Passages ,P5 were used for all experiments. For siRNA-mediated knockdown of G-protein a-subunits, HUVECs were transfected using the Lipofectamine RNAiMAX system (13778150; Invitrogen) with the following siRNA target sequences (all Qiagen, Venlo, The Netherlands): Control siRNA (1022076), Ga 11 :
For determination of VEGFR2 phosphorylation under flow conditions, m-slides 0.4-luer (Cat. 80176, IBIDI, Martinsried) were coated with 70 000 cells per slide and incubated overnight to allow cells to attach. The expression of Ga q and Ga 11 was suppressed with siRNAs on two consecutive days according to the manufacturer's protocol. One day after second transfection, cells were subjected to a shear stress of 12 dyne/cm 2 for 2 days. After 48 h, the cells were harvested for protein analysis. Key experiments were reproduced with an independent set of siRNAs directed against Ga q and Ga 11 (Qiagen SI02780988 and SI04193574; data not shown).
Tube formation in HUVECs
For tube formation assays, 24-well plates were coated with 200 mL of growth factor reduced GFR Matrigel (BD Biosciences) and incubated at 378C for 30 min to promote polymerization. Quiescent HUVECs were seeded at a density of 5 × 10 5 cells per well in the presence or absence of 50 ng/mL VEGF or FGF-2. After 8 h of incubation, a wide field image was taken and pictures were analysed using the ImageJ software (NIH). The term 'total network' refers to the number of interconnected ECs per view field.
Calcium mobilization and inositol monophosphate 1 production in HUVECs
HUVECs were seeded on 96-well plates and siRNA transfection was performed as described above.
For calcium measurements, cells were washed 72 h after transfection with PBS and loaded with 3 mM Fluo-4 AM in Hank's balanced salt solution (HBSS) containing 10 mM HEPES for 30 min at 378C. Cells were washed in HBSS and then transferred to an automated fluorescent plate reader (FlexStation-3; Molecular Devices). Cells were stimulated by ligands thrombin (1 U/mL), histamine (1 mM), or VEGF (20 ng/mL). In some cases, supernatants of VEGF-stimulated cells (with or without 1 mg/mL anti-VEGF antibody B20-4.1.1) were used to stimulate calcium mobilization in untreated HUVECs (10 mL of supernatant added to 90 mL of recipient medium). Cellular calcium transients were recorded as relative fluorescence units for 3 min, and the integrated area under the calcium transients was quantified by using SoftMaxPro (Molecular Devices) and expressed as area under the curve.
For the determination of the inositol monophosphate 3 (IP 3 ) metabolite IP 1 , cells were stimulated 72 h after transfection with agonists as described above and cumulative IP 1 production was determined 30 min later using the HTRF IP-One Terbium-based assay (Cisbio, Codolet, France) according to the manufacturer's protocol.
FITC dextran permeability in HUVECs
HUVECs (10 4 ) were seeded in 50 mL of EGM2 complete medium into the upper well of 96-well transwell plates (8 mm pore size, 3384, Corning). After siRNA-mediated knockdown, FITC dextran 70 kDa (2 mg/mL) and permeability factors thrombin (10 U/mL), histamine (10 mM), or VEGF (50 ng/mL) were mixed in 50 mL of EGM2 medium and added to the upper compartment of transwell. EGM2 medium (250 mL) was added to the lower compartment. After 90 min, the amount of passed FITC dextran to the lower compartment was measured (FlexStation-3, Molecular Devices).
Quantitative RT-PCR
Total RNA was isolated from HUVECs using the RNeasy Mini Kit (Qiagen). RNA was reverse-transcribed using the Transcriptor high fidelity cDNA synthesis kit (Roche) according to the manufacturer's instructions. RT-PCR was carried out using the LightCycler 480 Probes Master (Roche, Mannheim, Germany) with primers/probe combination designed by the Roche RT-PCR design centre online tool or Primer-BLAST (NCBI):
Immunostaining and immunohistochemistry
For immunostainings, HUVECs were grown on collagen-coated coverslip in 24-well plates. Seventy-two hours after siRNA transfection, cells were starved for 2 h in EGM2 medium and then stimulated with thrombin (5 U/mL), histamine (10 mM), VEGF (50 ng/mL), or TNF-a (10 ng/mL) for 10 min. In some cases, cells were pretreated with an Src inhibitor PP2 (1 mM) for 2 h. After stimulation (applicable), cells were washed with PBS and fixed with methanol for 15 min at 2208C, then permeabilized and blocked with Triton X-100 (1%) and 4% BSA for 30 min, and then washed two times with PBS. The cells were immunostained with indicated antibodies in Triton X-100 (1%) and 1% BSA for overnight. Next, cells were washed twice with PBS for 10 min and antibody binding was visualized with species matched, fluorescently labelled secondary antibodies. Nuclei were stained with Hoechst in Triton X-100 (1%) and 1% BSA for 1 h. Images were acquired using an Leica SP5 confocal microscope and analysed using ImageJ (NIH). For statistical evaluation of basal and agonist-induced Cdh5 relocalization, the intensity of Cdh5 staining along 40 representative cell -cell borders was determined per sample. For retina whole-mount stainings, retinae were dissected and fixed in 4% PFA for 2 h at 48C or in methanol at 2208C. After fixation, retinae were incubated in blocking buffer (1% BSA and 0.3% Triton X-100) for 1 h, washed three times in PBlec buffer (1% Triton X-100, 1 mM CaCl 2 , 1 mM MgCl 2 , and 1 mM MnCl 2 in PBS [pH 6.8]), and then incubated with IB4-488 or biotinylated isolectin B4 in PBlec buffer overnight at 48C. Primary antibodies were diluted in retina-blocking buffer and incubated overnight, then washed with retina washing buffer (0.5% BSA and 0.1% Triton X-100), and incubated with Alexa Fluor streptavidin conjugates or speciesspecific Alexa Fluor-coupled secondary antibodies for 1 h. Nuclei were visualized with Hoechst. For retinal BrdU staining, 300 mg of BrdU was injected i.p. into p6 pups 2 h before sacrifice. Following isolectin B4 staining, retinae were fixed for 30 min in 4% PFA, washed three times with PBS, incubated for 1 h in 6 M HCl and 0.1% Triton X-100, washed five times in PBS plus 0.1% Triton X-100, blocked, and incubated overnight with anti-BrdU antibody. Secondary detection was performed with Alexa Fluor-coupled secondary antibodies.
Immunoblotting and immunoprecipitation
For immunoblotting, cells were lysed in radioimmunoprecipitation (RIPA) lysis buffer (150 mM NaCl, 25 mM Tris -HCl, 1 mL of 0.5 M EDTA pH 8.0, 2% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, and 0.25% Triton X-100) containing protease inhibitors [4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride (AEBSF) 10 mg/mL, aprotinin 10 mg/mL, leupeptin 10 mg/mL, and pepstatin A 10 mg/mL] and 1 mM of Na 3 VO 4 . For the detection of tyrosine phosphorylation, cells were treated with 1 mM Na 3 VO 4 before they were harvested. Mouse retinae were homogenized with an Ultra Turrax in RIPA lysis buffer containing protease and phosphatase inhibitors. Lysates were incubated on a rotating shaker for 30 min at 48C, then centrifuged at 18.000 g for 10 min at 48C. Supernatants were boiled in Laemmli buffer for 5 min and then used for immunoblotting. Proteins were separated in 6 or 8% SDS -PAGE, then transferred onto nitrocellulose membranes, followed by overnight incubation with primary antibodies. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. Antibody binding was visualized by enhanced chemiluminescence reagent (Millipore) using Fuji medical X-ray films, and protein bands were quantified using the ImageJ software (NIH).
For protein immunoprecipitation, HUVECs were lysed in ice-cold RIPA buffer (1% Triton X-100, 150 nM NaCl, 50 mM Tris pH 7.4, 0.1% SDS, 0.25% sodium deoxycholate, 1 mg/mL of each leupeptin, aprotinin, and pepstatin, 1 mM AEBSF, and 1 mM Na 3 VO 4 ). Protein extracts were purified by centrifugation and incubated with 5 mg of anti-Ga q/11 antibody (Santa Cruz Biotechnology, C-19) in the presence of Protein A/G Plus Agarose (Santa Cruz Biotechnology). Precipitated proteins were then centrifuged and washed several times using ice-cold RIPA buffer. Finally, antibody-antigen complexes were eluted by boiling them in Laemmli buffer and samples were then subjected to western blotting. Separated proteins were detected using anti-Gaq (BD Transduction Laboratories, #612705, 1:200) or anti-VEGFR2 (CST, clone 55B11, 1 : 500, dissolved in 5% BSA) antibodies.
Ex vivo trypsin sensitivity assay
The analysis of VE-cadherin sensitivity to trypsin was performed as described previously. 12, 13 In brief, p6 retinae were incubated for 1 h at 378C in trypsin/EDTA-containing HBSS (0.05% trypsin and 20 mM glucose supplement) or HBSS only (no trypsin and 20 mM glucose supplement). After incubation, the retina was rinsed three times in FBS-containing medium (10% FBS and DMEM) to inactivate trypsin and the retina was lysed in RIPA buffer using microhomogenizer (VWR) for western blot analysis. 
Statistical analysis
If not indicated otherwise, data are presented as means + standard errors of the means (SEM). Comparisons between two groups were performed with two-tailed Student's t-test or ANOVA followed by Bonferroni post hoc test. 'n' refers to the number of independent experiments (i.e. transfections) or to the number of mice per group. P-values are indicated as follows: *P , 0.05; **P , 0.01; ***P , 0.001.
Results
To investigate how G-proteins of the G q/11 family contribute to VEGF signalling, we performed siRNA-mediated knockdown of Ga q and Ga 11 in HUVECs. This resulted in efficient knockdown ( Figure 1A ) , but did not alter the expression of other G-protein a subunits (see Supplementary material online, Figure S1A ) or cell morphology and expression of junctional proteins (see Supplementary material online, Figure S1B) . Knockdown of Ga q/11 resulted in impaired intracellular calcium mobilization, Src phosphorylation, and VE-cadherin (Cdh5) phosphorylation in response to classical Ga q/11 -coupled receptor agonists such as thrombin or histamine (see Supplementary material online, Figure S1C -G). Interestingly, Ga q/11 deficiency also clearly reduced VEGF-induced calcium mobilization ( Figure 1B) and IP 3 production ( Figure 1C) , as well as phosphorylation of MLC2 ( Figure 1D) , Src ( Figure 1E ), Cdh5 ( Figure 1F) , and the Ga q/11 effector PLCb 3 (see Supplementary material online, Figure S1H ). Loss of VEGF-induced Src activation seemed to be causal for loss of Cdh5 phosphorylation, since inhibition of Src by PP2 similarly reduced VEGF-induced Cdh5 phosphorylation ( Figure 1G) . In contrast, VEGF-induced phosphorylation of ERK1/2 and Akt/protein kinase B was not altered ( Figure 1H) .
We next investigated whether impaired VEGF signalling had consequences for VEGF-dependent endothelial functions such as barrier control, proliferation, or tube formation. We found that VEGF-induced Cdh5 relocalization from junctions was diminished 10 and 30 min after stimulation, whereas TNF-a-induced effects were preserved (Figure 2A) . In line with this we found in transwell assays that VEGF-induced increases in permeability for soluble dextran were near abrogated ( Figure 2B) . VEGF-induced proliferation was strongly reduced in the absence of Ga q/11 , whereas proliferation induced by FGF-2, another pro-angiogenic growth factor, was preserved ( Figure 2C) . Also, VEGF-induced tube formation was impaired, but not FGF-2-induced tube formation ( Figure 2D) .
In the following step, we addressed the question at what level VEGFR2 and Ga q/11 signalling intersect. One hypothesis is that G q/11 may be required to induce full activation of VEGFR2 by facilitating VEGFR2 autophosphorylation. 3, 4 We found that VEGF-induced VEGFR2 autophosphorylation was impaired in the absence of Ga q/11 , especially at residue Y951, and to lesser extent at Y1175 ( Figure 3A) . Conversely, overexpression of constitutively active Ga q facilitated VEGF-induced VEGFR2 phosphorylation, and this effect was strongly reduced by the Src inhibitor PP2 ( Figure 3B) . We also found that activation of G q/11 -coupled receptors by thrombin and histamine facilitated VEGF-induced VEGFR2 phosphorylation in a Ga q/11 -dependent manner ( Figure 3C ). Furthermore, we were able to detect a short-lived interaction between VEGFR2 and G q/11 (see Supplementary material online, Figure 2A ). Taken together, these findings suggest that G q/11--coupled receptors provide a co-stimulatory signal for VEGF-induced VEGFR2 phosphorylation and consecutive intracellular signalling events. To understand the mechanism of Ga q/11 -dependent facilitation of VEGFR2 phosphorylation, we investigated the possibility that VEGFR2 stimulation induces the release of agonists able to activate G q/11 -coupled receptors. We transferred conditioned medium from VEGF-stimulated HUVECs to unstimulated HUVECs and determined intracellular calcium mobilization as a read-out for G q/11 -dependent PLCb activation. To block calcium mobilization induced by VEGF itself, we performed these experiments in the presence of blocking anti-VEGF antibody B20-4.1.1. 14 We found that any calcium mobilization induced by supernatant of VEGF-stimulated HUVEC was countermanded by addition of B20-4.1.1 (Figure 3D) , indicating that conditioned media did not contain relevant concentrations of agonists at G q/11--coupled GPCRs. We also tested the hypothesis that Ga q/11 provides a constitutive, VEGF-independent facilitating effect on VEGFR2 phosphorylation. Since under static conditions basal VEGFR2 phosphorylation is below the detection limit of our assays, we exposed HUVECs to continuous shear stress, a condition known to induce sustained VEGFR2 autophosphorylation. 15 We found that chronic exposure to shear stress resulted in mild basal VEGFR2 phosphorylation in control HUVECs, and that this effect was reduced in Ga q/11 -kd cells (see Supplementary material online, Figure 2B ). These data suggest that a certain degree of tonic G q/11 activity exists in HUVECs and may contribute to the facilitating effect on VEGF-induced VEGFR2 phosphorylation.
To test whether Ga q/11 was also in vivo required for VEGF effects including opening of the endothelial barrier, we studied cutaneous fluid extravasation in tamoxifen-inducible, endothelial-specific Ga q/11--deficient mice (iEC-Ga q/11 -KO). 8 These mice showed that Evans blue extravasation into the dorsal skin was not only in response to thrombin receptor activation strongly diminished, but also in response to local VEGF application ( Figure 4A) . Reduced VEGF-induced extravasation in iEC-Ga q/11 -KOs was also observed in an ear model of FITC dextran extravasation ( Figure 4B) , and mutant mice showed reduced relocalization of junctional Cdh5 in dermal ear vessels ( Figure 4C) . Taken together, these findings show that both in vitro and in vivo Ga q/11 is required for VEGF-induced opening of the endothelial barrier.
To understand the in vivo consequences of disturbed VEGF signalling in Ga q/11 -deficient ECs, we studied postnatal angiogenesis in retinae of iEC-Ga q/11 -KOs. The retina is avascular at birth, and a single superficial layer of blood vessels grows progressively from the centre towards the periphery from P1 until P7. 16 To induce recombination in ECs, newborn mice from intercrosses between Tie2CreERT2 +/2 ; Gnaq fl/fl ; Gna11 +/ 2 and Gnaq fl/fl ;Gna11 +/ 2 were treated with tamoxifen on P1 -P3, and retinae were analysed on P6. 17 We found that endothelium-specific inactivation of Ga q and Ga 11 (iEC-Ga q/11 -KO) or of Ga q only (iEC-Ga q -KO) resulted in a clear reduction of retinal angiogenesis compared with littermate control mice or Ga 11 single-deficient mice (see Supplementary material online, Figure 3A) . Because of the poor odds of obtaining littermate controls and iEC-Ga q/11 -KOs from these matings, all further analyses and quantifications were performed in iEC-Ga q -KOs and controls generated by intercrossing Tie2CreERT2 +/2 ; Gnaq fl/fl mice. Adult iEC-Ga q -KOs did not differ with respect to blood pressure, heart rate, or body weight from control mice. Retinae of 6-day-old iEC-Ga q -KOs showed significantly reduced EC coverage, vessel branching, and tip cell numbers, and also the number of filopodia per tip cell was decreased ( Figure 5A-E) .
In line with an impaired VEGF signalling, ECs of iEC-Ga q -KOs showed reduced proliferation ( Figure 6A ) and increased apoptosis ( Figure 6B) . Retinal vessel pericyte coverage and VEGFR2 expression were not altered (see Supplementary material online, Figure 3B and C), but deep plexus formation was significantly delayed (see Supplementary material online, Figure 3D ). To investigate whether retinal vessels of iEC-Ga q -KO mice showed signs of reduced permeability, we analysed retinal Cdh5 phosphorylation and found it to be diminished in iEC-Ga q -KO mice ( Figure 6C) . What is more, Src phosphorylation was significantly reduced in immunoblotting and immunohistochemistry ( Figure 6C and D) , whereas Akt phosphorylation was not changed ( Figure 6C ). We also assessed basal fluid extravasation at the angiogenic front after systemic FITC dextran injection and found a reduction of leakage sites in retinae of mutant mice ( Figure 6E) . Since junction-associated Cdh5 was shown to be more trypsin resistant than non-junctional Cdh5, 13, 18 we analysed the proteolytic sensitivity of Cdh5 by trypsin. We found that protein lysates from iEC-Ga q -KOs showed reduced trypsin-mediated Cdh5 cleavage ( Figure 6F) , indicative of reduced availability of disengaged Cdh5.
Taken together, our data reveal an unexpected role of Ga q/11 in mediating the permeability-increasing and pro-angiogenic effects of VEGF in vitro and in vivo.
Discussion
The role of G q/11 in ECs has been addressed in a number studies, but previous analyses mainly focused on their role in classical GPCR-dependent signalling cascades. 8, 11 We show in this study that endothelial Ga q/11 does not only mediate the permeability-enhancing effects of GPCR agonists such as thrombin or histamine, but also plays an important role in the signalling events induced by VEGF. We show that Ga q/11 is required for VEGF-induced proliferation, barrier opening, and tube formation, which supports and extends findings from previous studies describing a role of Ga q/11 in VEGF-induced migration and proliferation. 5, 6 With respect to the mechanism by which Ga q/11 contributes to VEGF-induced effects, we found that activation of Ga q/11 by GPCR agonists facilitated VEGF-induced autophosphorylation at Y951 and Y1175, two residues crucial for VEGFR2 downstream signalling. 3, 4 This finding is in line with a previous study, demonstrating that bradykinin, another agonist at Ga q/11 -coupled GPCRs, induces tyrosine phosphorylation of VEGFR2. 19 How Ga q/11 brings about this facilitation of VEGFR2 phosphorylation is not fully clear. Previous studies 6 and our own analyses indicate that VEGF treatment induces a shortlived interaction between Ga q/11 and VEGFR2, but whether this interaction is a prerequisite for consecutive phosphorylation events is unclear. Our data also suggest that activation of Src family kinases 10 plays an important role in Ga q/11 -dependent VEGFR2 phosphorylation. The exact mechanisms of Ga q/11 -dependent Src activation have not been studied in HUVEC, but data obtained in other cell types point to a role of PLCb activation. Studies in rat PC12 cells showed that bradykinin, a typical agonist at G q/11 -coupled receptors, induces c-Src activation through PLCb-dependent intracellular calcium mobilization and consecutive autophosphorylation of Pyk2. 20 Studies in rat endometrial cells suggested a role of PLCb-dependent PKC activation in Ga q -dependent Src activation. 21 Bhattacharya et al. 22 demonstrated that PLCb3 is phosphorylated at various residues upon VEGF stimulation, and that VEGF-induced IP 3 production depended on PLCb3. In line with this, we found that VEGF-induced PLCb phosphorylation as well as VEGF-induced IP 3 production and calcium mobilization were reduced after knockdown of Ga q/11 . How Ga q/11 is activated in VEGF-stimulated cells is currently unclear. One potential explanation is a VEGF-induced release of Ga q/11--coupled receptor agonists, but supernatant transfer experiments did not provide evidence for significant VEGF-induced secretion of factors that activate Ga q/11 -coupled receptors in an autocrine manner. However, it cannot be excluded that such factors escaped detection because of their localized release or their short half life time. An alternative explanation might be a constant basal tone of Ga q/11 activation, either due to autocrine stimulation or constitutive receptor activity. 23 In line with this notion, we observed reduced basal IP 1 accumulation in Ga q/11 -deficient HUVEC and reduced basal VEGFR2 phosphorylation in HUVEC cultured under flow conditions. These data suggest that a tonic activity of Ga q/11 signalling exists in the absence of exogenous ligands, and that this tonic Ga q/11 activity facilitates basal VEGFR2 phosphorylation.
Our study shows that VEGF-induced opening of the endothelial barrier is not only impaired in cultured ECs, but also in two in vivo models of VEGF-induced fluid extravasation. That endothelial Ga q/11 mediates the permeability-enhancing effects of GPCR agonists thrombin, histamine, or platelet-activating factor has been previously shown in EC-Ga q/11 -KOs, 8 but the role of Ga q/11 in VEGF signalling has not yet been addressed in vivo. In further support of disturbed VEGF signalling, we found that reduced postnatal retinal angiogenesis in iEC-Ga q -KO and iEC-Ga q/11 -KO mice. It is in this context interesting to note that also G-proteins of the G 12/13 family, which often couple to the same GPCRs as the G q/11 family, 9 play an important role in mediating VEGFdependent effects, though through a completely different mechanism: whereas Ga q/11 facilitates VEGFR2 autophosphorylation and downstream signalling, Ga 13 is required for VEGFR2 expression in angiogenic ECs. 17 Taken together, these findings indicate that GPCR signalling in ECs positively regulates VEGF signalling both on the level of transcription and protein phosphorylation, thereby providing important modulatory effects during angiogenesis.
Whether defective angiogenesis in iEC-Ga q -KOs is primarily due to reduced VEGF signalling, disturbed barrier opening, or other factors is currently unclear. Given the central role of VEGF in mediating EC proliferation, survival, and migration, 2 -4 it seems likely that impaired VEGFR2 signalling contributes to observed phenotypes. In line with this notion, we found reduced proliferation and increased apoptosis in retinal ECs of mutant mice. However, the changes in proliferation and apoptosis were not severe enough to compromise endothelial barrier function in general, as shown by the absence of generalized FITC dextran leakage in vitro and in vivo. In addition, loss of permeability-enhancing effects mediated by GPCR agonists and VEGF might contribute to disturbed angiogenesis. Previous studies showed that increased permeability plays an important role in angiogenesis, since blocking antibodies directed against Cdh5 prevented angiogenesis in vitro and in vivo. 24 We found that in the developing retina of iEC-Ga q -KOs Cdh5 phosphorylation and trypsin sensitivity were reduced, and that this was associated with a lower number of vascular leakage sites at the angiogenic front. It is furthermore possible that other functional alterations, such as impaired adhesion, contractility, or secretion, contribute to reduced angiogenesis in iEC-Ga q/11 -KOs. However, the fact that basal endothelial morphology, expression of endothelial marker genes, proliferation, and tube formation were unchanged in Ga q/11 -kd HUVEC indicates that loss of Ga q/11 does not result in general disturbance of endothelial functions.
Taken together, our study reveals a so far unknown role of endothelial G q/11 in mediating the permeability-increasing and pro-angiogenic effects of VEGF in vitro and in vivo. Based on these findings, we hypothesize that selective pharmacological targeting of G q/11 -coupled receptors with an endothelial-restricted expression pattern might prove useful to modulate angiogenic responses under pathological conditions such as tumour angiogenesis or retinal disease.
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